# Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?

> **NCT00571688** · PHASE4 · COMPLETED · sponsor: **Vanderbilt University** · enrollment: 50 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Risperdal (risperidone) Consta
- **DRUG:** Treatment as usual

## Key facts

- **NCT ID:** NCT00571688
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00571688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00571688, "Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00571688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*